Home » Oncology Based In-vivo CRO Market Trends, Report 2022-2027

Oncology Based In-vivo CRO Market Trends, Report 2022-2027

by Alex Hales

Oncology Based In-vivo CRO Market Overview:

According to the latest report by IMARC Group, titled “Oncology Based In-vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the global oncology based in-vivo CRO market. The report also includes competitor and regional analysis, and contemporary advancements in the market.

The global oncology based in-vivo CRO market size reached a value of US$ 1.05 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.69 Billion by 2027, exhibiting a CAGR of 7.81% during 2022-2027.

Oncology refers to a branch of medicine that deals with the study, diagnosis, and treatment of cancer using ultrasound, positron emission tomography (PET) scanning, magnetic resonance imaging (MRI), computed tomography (CT) scanning, biopsy, endoscopy, and X-ray. It helps patients tolerate and ease cancer side effects by offering immunotherapy, radiotherapy, hormonal therapy, and oral therapies. At present, oncology based in-vivo CRO is gaining immense traction globally due to the development of several investigational compounds for treating cancer by contract research organizations (CROs).

Request a PDF Sample for more detailed market insights: https://www.imarcgroup.com/oncology-based-in-vivo-cro-market/requestsample

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Oncology Based In-Vivo CRO Market Trends and Drivers:

The global oncology based in-vivo CRO market is primarily driven by the rising prevalence of cancer among individuals. Moreover, there is a rise in genetic engineering innovations for altering the characteristics of organisms and manipulating deoxyribonucleic acid (DNA). In line with this, the improving focus on the study of oncogene to regulate the growth, proliferation, and differentiation of cells has catalyzed the market growth.

Besides this, governments of several countries are investing in research and development (R&D) activities. This, along with the increasing expertise of contract research organizations (CROs) in cancer treatment, is driving market growth. Furthermore, the easy availability of medications and the expanding healthcare industry are other major growth-inducing factors.

Other factors, including the surging adoption of telehealth and virtual clinical trials in the healthcare sector, rising usage of generics, and high failure rate of existing treatment options, are also anticipated to create a favorable market outlook.

Explore Full Report with TOC & List of Figures: https://www.imarcgroup.com/oncology-based-in-vivo-cro-market

Important Note: If the link is not clickable please open it in a new tab, you will get detailed analysis of the market, growth analysis graphs, historical period analysis, forecast period analysis, major market segmentation, top leading key players of the market, table of content, list of figures, and list of tables.

Global Oncology Based In-Vivo CRO Market 2022-2027 Analysis and Segmentation:

 Competitive Landscape:

 The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

  • Champions Oncology Inc.
  • Charles River Laboratories International Inc.
  • Crown Bioscience Inc.
  • Eurofins Scientific
  • Evotec SE
  • ICON Plc
  • Labcorp Drug Development (Laboratory Corporation of America Holdings)
  • Living Tumor Laboratory
  • Taconic Biosciences Inc.
  • The Jackson Laboratory
  • WuXi AppTec
  • Xentech

The report has segmented the market on the basis of region, indication, model and application.

Breakup by Indication:

  • Blood Cancer
  • Solid Tumors
  • Others

Breakup by Model:

  • Syngeneic
  • Xenograft
  • Patient Derived Xenograft (PDX)
  • Others

Market Breakup by Application:

  • Hospitals
  • Rehabilitation Centers

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

 Key highlights of the report:

  • Market Performance (2016-2021)
  • Market Outlook (2022- 2027)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Read Also: Silicon Wafer Reclaim Market Size, Share and Forecast 2027

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800


Related Posts

Leave a Comment